Key Non-small Cell Lung Cancer Treatment Market Players:
- Roche
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co.
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer
- Novartis AG
- Takeda
- Eli Lilly
- Daiichi Sankyo
- Amgen
- BeiGene
- Sanofi
- Regeneron
- Celltrion
- Eisai Co., Ltd.
- Dr. Reddy’s
- Biocon
- CSPC Pharma
- Pharmaniaga
- CSL
A highly consolidated market is experienced in the non-small cell lung cancer treatment market. More than 50% of the market share is accumulated by top players like Roche, Merck, and so on. The key strategies that are implemented to derive a competitive edge include immunotherapy dominance, targeted therapy expansion, biosimilar competition, and expansion in the Asia Pacific market. Companies such as Merck launched Keytruda and BMS’s Opdivo led to a significant increase in their sale and directed revenue accumulation of more than USD 20 million in 2023. AstraZeneca focused on targeted therapy expansion through launching Tagrisso and Alunbrig, which delivered a competitive edge to the business. Business firms, includingDr. Reddy’s, Biocon relied on cost-controlled production and delivered an affordable range of products to the market.
